Respected GWI researcher to investigate two promising treatments for GWI with premier DoD-CDMRP funding
91outcomes Editor’s Note:
This Gulf War Illness treatment study is funded by the peer-reviewed, Congressionally Directed, U.S. Department of Defense Gulf War Illness Medical Research Program (CDMRP-GWI), the nation’s premier GWI research program.
Low Dose Naltrexone (LDN), one of the two drugs to be investigated for GWI in this study, has been found to have significant health benefits in patients with Multiple Sclerosis (MS) and several other chronic multi-symptom health conditions. For more information on LDN, see: www.lowdosenaltrexone.org.
The study’s Principal Investigator, Dr. William Meggs, is a respected scientist who has served on the Congressionally chartered U.S. Department of Veterans Affairs (VA) Research Advisory Committee on Gulf War Veterans’ Illnesses (RAC-GWVI) for many years.
GULF WAR ILLNESS STUDY
If you served in the 1991 Gulf War and developed symptoms of Gulf War related illness, you may be eligible to participate in a treatment protocol conducted by Dr. William J. Meggs at the Brody School of Medicine at East Carolina University, in Greenville, North Carolina and sponsored by the Department of Defense.
After a telephone screening interview, participants who qualify and wish to participate will be brought to the Brody School of Medicine at East Carolina University, in Greenville, North Carolina, to undergo an evaluation.
The study will test the benefits of two approved generic drugs, naltrexone and dextromethorphan, in treating the symptoms of Gulf War illnesses. These drugs will be studied because they are beneficial in illnesses similar to Gulf War illnesses, safe, readily available, and reduce inflammation in the brain that may be responsible for some of the symptoms that Gulf War Veterans are having.
If you feel that you may qualify for this study and are interested in participating, please contact Dr. William J. Meggs either by email [ firstname.lastname@example.org, copy to email@example.com ], or telephone [252-744-2954].